Gene · 2303
FOXC2: forkhead box C2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FOXC2: forkhead box C2. Genes, record 2303. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2303
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99958 | Forkhead box protein C2 | 501 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents44
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 19650 | Q99958 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14979 | Q99958 | Espacenet |
| JP 2025521922 A | 2025-07-10 | 48 | Q99958 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 19650 | Q99958 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14979 | Q99958 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14979 | Q99958 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 6285 | Q99958 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 14818 | Q99958 | Espacenet |
| US 12024722 B2 | 2024-07-02 | 297 | Q99958 | Espacenet |
| JP 2024506208 A | 2024-02-09 | 96 | Q99958 | Espacenet |
1 to 10 of 44
See all 44 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,592
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FOXC2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 29 | 2025 |
| R01HL131652 | Defining the Mechanisms of Lymphatic Vascular Growth and Function | 7 | 2025 |
| R01HL133216 | Molecular Mechanisms Controlling Lymphatic Vascular Function in Health and Disease | 7 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 5 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 4 | 2025 |
| P30CA056036 | Translational Research in Cancer | 4 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 4 | 2025 |
| P30EY007003 | University of Michigan Vision Research Center | 4 | 2025 |
1 to 10 of 1,592Source NIH's project files
See all 1,592 nih grantsPapers2,402
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SCTR-Expressing Astrocyte-Serotonergic Neuron Signaling Drives Sexual Dimorphism in Depression Through KAT7/H4ac-Foxc2 Epigenetic Axis in an AMPK-Dependent Manner. | Adv Sci (Weinh) | 2026 | 42801528 | PubTator, text mining | PubMed |
| Molecular Distinctions, Diagnosis, and Mechanism-Based Therapies in Lipedema and Obesity. | Curr Issues Mol Biol | 2026 | 42793248 | PubTator, text mining | PubMed |
| Engineering lymphatic collecting vessel phenotypes through combined hyaluronic acid cues and oscillatory shear stress. | Cell Rep Methods | 2026 | 42697195 | PubTator, text mining | PubMed |
| Transcriptomic profiling of thyroid eye disease orbital fibroblasts identifies sorafenib as a novel therapeutic. | Front Endocrinol (Lausanne) | 2026 | 42688036 | PubTator, text mining | PubMed |
| Restoration of oscillatory shear stress in humans activates an endothelial protective genetic program and prevents DVT. | Blood | 2026 | 42611796 | PubTator, text mining | PubMed |
| Yellow Nail Syndrome in Childhood: A Case Report Highlighting Diagnostic Challenges and the Possible Role of Nail Development-Related Genetic Variants. | Skin Appendage Disord | 2026 | 42610102 | PubTator, text mining | PubMed |
| Out"FOX"ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy. | Front Med (Lausanne) | 2026 | 42454125 | PubTator, text mining | PubMed |
| Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals. | Blood | 2026 | 42101967 | PubTator, text mining | PubMed |
| The role of the cardiac lymphatic system in heart failure "reverse remodeling": from developmental signals to druggable targets. | Front Immunol | 2026 | 42099625 | PubTator, text mining | PubMed |
| FOXC2 represses NFAT1-dependent transcription through a DNA-facilitated protein-protein interaction. | Nucleic Acids Res | 2026 | 42023653 | PubTator, text mining | PubMed |
1 to 10 of 2,402
See all 2,402 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2303
GET https://conductscience.org/api/genes/v1/2303/patents?page=2